Literature DB >> 12601391

Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes.

F Grünebach1, M R Müller, A Nencioni, P Brossart.   

Abstract

Dendritic cells (DC) are professional antigen-presenting cells playing a central role in the induction of antigen-specific cytotoxic T-lymphocytes (CTL). We analyzed the efficiency of tumor RNA transfection into DC using different sources of RNA as well as delivery strategies including electroporation, lipofection and CD71-receptor-based delivery. To evaluate the sensitivity of these approaches, we utilized in vitro transcribed enhanced green fluorescence protein (EGFP)-RNA and whole tumor RNA from EGFP-transfected renal cell carcinoma cell line N43. We demonstrate that electroporation was the most effective way yielding about 30% EGFP positive cells while less than 1% of DC expressed EGFP using the transferrin receptor transfection system. Delivery of RNA with liposomes resulted in 17.5% of EGFP positive cells depending on the RNA amount. However, when these approaches were applied to transduce DC with RNA derived from the A498 cell line for T-cell priming, tumor-specific CTL could be induced using all delivery strategies suggesting that this technology has the potential to induce cytotoxic T-cell response even when low level of antigen is delivered. Furthermore, we demonstrate that amplification of whole tumor messenger RNA (mRNA) as well as the use of total instead of purified mRNA can be utilized for stimulating tumor-specific CTL responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601391     DOI: 10.1038/sj.gt.3301901

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

2.  Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.

Authors:  Miwako Narita; Nozomi Tochiki; Anri Saitoh; Norihiro Watanabe; Masami Kaji; Noriyuki Satoh; Akie Yamahira; Takeshi Nakamura; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2008-12-05       Impact factor: 3.064

3.  A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.

Authors:  Rajeev K Tyagi; Rajesh Parmar; Naisargee Patel
Journal:  Hum Vaccin Immunother       Date:  2016-11-30       Impact factor: 3.452

Review 4.  Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Authors:  Bernhard Frankenberger; Sybille Regn; Christiane Geiger; Elfriede Noessner; Christine S Falk; Heike Pohla; Miran Javorovic; Tobias Silberzahn; Susanne Wilde; Alexander Buchner; Michael Siebels; Ralph Oberneder; Gerald Willimsky; Antonio Pezzutto; Thomas Blankenstein; Dolores J Schendel
Journal:  World J Urol       Date:  2005-07-05       Impact factor: 4.226

Review 5.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.

Authors:  Christiane Geiger; Sybille Regn; Andreas Weinzierl; Elfriede Noessner; Dolores J Schendel
Journal:  J Transl Med       Date:  2005-07-26       Impact factor: 5.531

7.  Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

Authors:  Jean-Philippe Carralot; Benjamin Weide; Oliver Schoor; Jochen Probst; Birgit Scheel; Regina Teufel; Ingmar Hoerr; Claus Garbe; Hans-Georg Rammensee; Steve Pascolo
Journal:  Genet Vaccines Ther       Date:  2005-08-22

8.  Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia.

Authors:  Silvija Jarnjak-Jankovic; Rolf D Pettersen; Stein Saebøe-Larssen; Finn Wesenberg; Gustav Gaudernack
Journal:  BMC Cancer       Date:  2005-02-18       Impact factor: 4.430

Review 9.  mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

Authors:  Sandra Van Lint; Carlo Heirman; Kris Thielemans; Karine Breckpot
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

10.  Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.

Authors:  Jacoba G Slagter-Jäger; Alexa Raney; Whitney E Lewis; Mark A Debenedette; Charles A Nicolette; Irina Y Tcherepanova
Journal:  Mol Ther Nucleic Acids       Date:  2013-05-07       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.